Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways.
about
Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancerManagement of metastatic carcinoma of the uveal tract: an evidence-based analysis.The role of desmoglein-3 in the diagnosis of squamous cell carcinoma of the lung.Phase 1 study of combination treatment with PTK 787/ZK 222584 and cetuximab for patients with advanced solid tumors: safety, pharmacokinetics, pharmacodynamics analysis.Synthesis and biological activity of N(4)-phenylsubstituted-6-(2,4-dichloro phenylmethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and antiangiogenic and antitumor agents.Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer.N⁴-Aryl-6-substitutedphenylmethyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as receptor tyrosine kinase inhibitors.TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenograftsCellular responses to EGFR inhibitors and their relevance to cancer therapy.Predicting gene promoter methylation in non-small-cell lung cancer by evaluating sputum and serum.Lung cancer: future directions.Antitumor effect of vandetanib through EGFR inhibition in head and neck squamous cell carcinomaAngiogenesis and its therapeutic opportunitiesReview of erlotinib in the treatment of advanced non-small cell lung cancer.Engineering Intrinsically Zirconium-89 Radiolabeled Self-Destructing Mesoporous Silica Nanostructures for In Vivo Biodistribution and Tumor Targeting Studies.Angiogenesis in the treatment of non-small cell lung cancer.Antibodies targeting cancer stem cells: a new paradigm in immunotherapy?Functional drug-gene interactions in lung cancer.Targeting angiogenesis for treatment of human cancerCombination therapy with vidaza and entinostat suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model.Apatinib plus icotinib in treating advanced non-small cell lung cancer after icotinib treatment failure: a retrospective study.Safety and efficacy of sequential chemotherapy with carboplatin plus gemcitabine followed by weekly paclitaxel in advanced non-small cell lung cancer.Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer.Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib.
P2860
Q28728593-E8470EC7-958E-4F2E-BCE4-A5A48BF6A2CAQ33296064-B2BEA44E-C9D8-4E03-94E0-E154BECD3088Q33426224-2580C089-A509-4275-8B09-F52AD82F07FCQ33622614-0A60C88A-20AC-4B74-A268-A3C9CCE5FEB7Q33847057-6375BB0C-B969-46C6-A869-4C44C63962A4Q35584074-195E5ACC-120E-4C4D-8921-981B8232BAACQ35747449-7831CACB-DCCF-4F2B-9B02-A1661994E1A9Q35894601-C9000B7A-6664-4792-8C88-6BE00E976BFFQ36003118-CF86EEB9-80B3-4CAF-AE5C-F1DFD1BE1987Q36610297-C37537E0-9F8D-4EEF-9302-E5A41450F3CCQ36857549-E16154CB-070A-457F-BC02-39C28854A1E3Q36909227-FBD53ECD-7BD8-4365-949A-29C28EAEC7DCQ37101283-EBB3A058-C5DA-4619-9D61-992F1ACFFEADQ37290444-69E36626-34F2-47D9-80CA-84B97A034C9BQ37404653-99D701B7-5D06-40CF-872F-13099E29427BQ37435385-A0E41A35-B63D-4588-A202-CE8E93A72BDBQ37666618-ED06E5F0-5F52-421F-9DCA-B931AD7D901CQ37999073-0094AF3B-034A-4C26-9979-35C69F610BCAQ38125442-573230CA-491C-45B6-95D7-931F16EF1D76Q39609163-98AE43DA-80E2-406F-8CE5-2860CB9DCAEBQ42673264-E05DF689-22FF-4D3C-A21B-1D0C6F763995Q46764329-534C11E7-EC35-43B1-A544-58839682FB4AQ47994454-A3DAD36A-C3BC-4004-914D-5CE2F4BACB96Q53354363-6A1124DE-3CE3-4CB6-9AB0-23833BD7EC46
P2860
Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Combining targeted agents: blo ...... helial growth factor pathways.
@ast
Combining targeted agents: blo ...... helial growth factor pathways.
@en
type
label
Combining targeted agents: blo ...... helial growth factor pathways.
@ast
Combining targeted agents: blo ...... helial growth factor pathways.
@en
prefLabel
Combining targeted agents: blo ...... helial growth factor pathways.
@ast
Combining targeted agents: blo ...... helial growth factor pathways.
@en
P1476
Combining targeted agents: blo ...... helial growth factor pathways.
@en
P2093
Alan Sandler
P304
4421s-4425s
P356
10.1158/1078-0432.CCR-06-0796
P407
P433
P577
2006-07-01T00:00:00Z